Allergy Therapeutics Announces Winner of EAACI Early Career Research Award
Why we think this is neutral
This RNS announcement is a general update on Allergy Therapeutics' collaboration with EAACI to award a research grant, rather than a mandatory news type such as a trading update or results announcement. As such, the sentiment is neutral as there is no significant financial or operational information provided.
Key Points
- Allergy Therapeutics and EAACI announce winner of EAACI Early Career Research Award
- The award recipient is Dr. Janice Layhadi, an early career researcher in the field of biomarker discovery in allergen immunotherapy
- The award provides an unrestricted research grant of up to €30,000 to support young researchers in advancing allergy and immunology research
Summary
Allergy Therapeutics, the commercial biotechnology company specialising in allergy immunotherapies, has announced the winner of the EAACI Early Career Research Award. The award, presented in collaboration with the European Academy of Allergy and Clinical Immunology (EAACI), aims to support young researchers in advancing allergy and immunology research. The recipient of this year's award is Dr. Janice Layhadi, an early career researcher focused on biomarker discovery in allergen immunotherapy.